- Oops!Something went wrong.Please try again later.
A COVID-19 vaccine candidate that employs the company's adjuvant technology produced positive clinical trial results.
Goldman Sachs analyst Jason English initiated coverage of Sovos Brands Inc (NASDAQ: SOVO) with a Buy rating and $19 price target, suggesting a 34% upside. The analyst sees a "compelling distribution and product-cycle fueled growth story" from the company over the next three years. Jason expects "top-tier organic revenue growth" of 10% and EBITDA growth of 15% through fiscal 2024, adding that the growth is underappreciated by the market at the stock's current valuation level. Telsey Advisory init
A report says Novavax has failed to produce a vaccine with the purity levels demanded by the Food and Drug Administration.
Atea Pharmaceuticals said Tuesday its Merck-rivaling antiviral Covid pill missed in a midstage test, leading AVIR stock to crash.
Moderna (NASDAQ: MRNA) stock might look a bit expensive these days. At the same time, some investors wonder whether Moderna may have reached peak sales of its coronavirus vaccine. Right now, it's too early to predict if and when coronavirus vaccine sales will slow.
Vertex Pharmaceuticals' (NASDAQ: VRTX) woes began about a year ago when it announced the failure of an alpha-1 antitrypsin deficiency (AATD) candidate in clinical trials. Since that first problem, Vertex shares have dropped 33%. Vertex boasts a billion-dollar cystic fibrosis (CF) business.
Photo by Towfiqu barbhuiya on Unsplash Broad agreement in the world of science can be a rarity. However, one thing that public health leaders active in the fight against COVID-19 can agree on, is the urgent need for oral, pill-based treatments that are effective at halting disease progression, can get — and keep — people out of the hospital and can reduce mortality. One key group of COVID-19 patients who are in desperate need of treatment options are those moderately severe patients in hospital
The FDA approval of nasal spray Tirvaya didn't include data needed for the company to receive the second tranche in its credit facility.
While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.
Infinity Pharmaceuticals (NASDAQ: INFI) got off to a market-beating start this week as its shares zoomed 3.8% higher Monday, on the back of new analyst coverage that made an extremely bullish case for investing in the biotech. H.C. Wainwright's Michael King Jr. is the prominent new Infinity bull. King points out that the company's lead pipeline candidate, the cancer treatment eganelisib, "has shown compelling activity both as a single agent as well as in combination with commonly used immune checkpoint inhibitors."
(Reuters) -Roche raised its 2021 sales forecast on Wednesday after demand for COVID-19 tests and medicines was boosted by the highly contagious Delta variant and the wider business performed well, helping the Swiss drugmaker beat revenue expectations. The company now predicts overall 2021 sales will grow in the mid-single digit range at constant exchange rates, having previously expected them to rise in the low to mid-single digit percentage range. "The demand for coronavirus tests remained high in the third quarter due to the Delta variant," Chief Executive Severin Schwan said.
Vertex Pharmaceuticals (NASDAQ: VRTX) is one of the largest biopharma businesses in the world, but you've probably never heard of anyone taking the medications that it makes. Today, Vertex's shares go for around $180. Right now, Vertex has four drugs that are approved for sale, all of which are combinations of molecules it developed to treat cystic fibrosis (CF).
The company applied in April for Food and Drug Administration approval to sell the new product. Now that process could take a bit more time.
Shares in Revance Therapeutics dropped more than 40% Monday, after the FDA rejected a license for the group’s proposed treatment for frown lines.
The FDA is moving to soon allow people to have a Covid-19 booster shot different from the vaccine they initially received, according to reports.
Public-health experts hope that a Covid-19 pill could be an affordable, convenient tool to reduce the human cost of the virus.
The global tally for the coronavirus-borne illness climbed above 241.2 million on Tuesday, while the death toll edged above 4.90 million, according to
Bad news the company received today from the FDA surprised investors more than it probably should have.
A Food and Drug Administration advisory committee voted unanimously Friday that allowing adults who were initially vaccinated with the Johnson & Johnson one-dose vaccine against COVID-19 to get a booster is safe and effective, freeing the way for the agency to authorize its use.
Federal regulators are expected to authorize the mixing and matching of COVID-19 booster doses this week in an effort to provide flexibility as the campaign for extra shots expands. The upcoming announcement by the Food and Drug Administration is likely to come along with authorization for boosters of the Moderna and Johnson & Johnson shots and follows the OK for a third dose for the Pfizer vaccine for many Americans last month. The FDA was expected to say that using the same brand for a booster was still preferable, especially for the mRNA vaccines from Pfizer and Moderna that have proved most effective against the coronavirus.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is pleased to announce that GIVLAARI® (givosiran) has now received a positive recommendation for reimbursement from the Canadian Agency for Drugs and Technologies in Health (CADTH). GIVLAARI® is approved by Health Canada for subcutaneous use for the treatment of acute hepatic porphyria (AHP) in adults.1